https://mugglehead.com/blue-moon-metals-springer-tungsten-mill-refurbishment-contract/ Mugglehead Media en 2026-10-26T21:17:45.658Z Blue Moon Metals signs Springer tungsten mill refurbishment contract CVE: MOON, NASDAQ: BMM, LON: TUN, Blue Moon Metals, Tungsten West, Tungsten, Mill refurbishment, Nevada, Mine restart https://mugglehead.com/intel-classiq-quantum-acquisition-terms/ Mugglehead Media en 2026-10-26T21:00:27.667Z Intel agrees to acquire Classiq with quantum deal price undisclosed NASDAQ: INTC, CVE: QNC, NYSEAMERICAN: QNC, CVE: PLUR, OTCMKTS: PLCKF, Intel Corporation, Classiq, Quantum eMotion Corp, Plurilock Security Inc, Quantum computing https://mugglehead.com/microsoft-voluntary-exit-offer-eligibility-cost-timing/ Mugglehead Media en 2026-10-26T20:01:42.768Z Microsoft offers voluntary buyouts across four countries NASDAQ: MSFT, NASDAQ: META, Microsoft, Meta Platforms, Voluntary buyouts, AI infrastructure, Cloud computing https://mugglehead.com/forum-markets-fireworks-ai-contract-payment-delivery/ Mugglehead Media en 2026-10-26T19:17:10.695Z Forum Markets reports US$94.4M Fireworks AI contract over 36 months NASDAQ: FRMM, NASDAQ: SLNH, Forum Markets, Soluna Holdings, Fireworks AI, AI infrastructure, GPU capacity, Data centres https://mugglehead.com/dongfang-electric-eco-dc-solutions-canadian-gas-turbines/ Mugglehead Media en 2026-10-26T17:49:04.738Z Dongfang Electric turbine pact covers 30 units for Canadian data centres HKG: 1072, SHA: 600875, NYSE: GEV, Dongfang Electric Corporation Limited, GE Vernova Inc, Eco DC Solutions, Gas turbines, Data centres, Power generation, Canada https://mugglehead.com/gold-4000-speculative-positioning-newmont-agnico-eagle/ Mugglehead Media en 2026-10-26T15:04:01.143Z Gold trades above US$4,000 after eight-week speculative retreat NYSE: NEM, TSE: AEM, NYSE: AEM, Newmont Corporation, Agnico Eagle Mines, Gold, Futures positioning, Gold mining https://mugglehead.com/ascendis-pharma-transcon-pth-five-year-kidney-function-data/ Mugglehead Media en 2026-10-26T13:37:07.206Z Ascendis Pharma reports kidney-function gains sustained for up to five years NASDAQ: ASND, NASDAQ: MBX, NASDAQ: BBIO, NASDAQ: IBB, Ascendis Pharma, MBX Biosciences, BridgeBio Pharma, Hypoparathyroidism, Kidney function, Clinical trials https://mugglehead.com/tempus-ai-xr-rna-cancer-profiling-europe-ivdr-certification/ Mugglehead Media en 2026-10-26T13:25:46.158Z Tempus AI receives European IVDR certification for xR cancer profiling NASDAQ: TEM, NASDAQ: ILMN, NASDAQ: IBB, Tempus AI, Illumina, iShares Biotechnology ETF, Cancer diagnostics, RNA sequencing, IVDR, Europe https://mugglehead.com/meta-platforms-equity-offerings-forward-sales-class-c/ Mugglehead Media en 2026-10-26T12:51:30.137Z Meta Platforms launches US$35B equity offerings and plans US$60B program NASDAQ: META, NYSE: AESI, Meta Platforms, Atlas Energy Solutions, AI infrastructure, Equity financing, Data centres, Dilution https://mugglehead.com/pinnacle-silver-and-gold-el-potrero-drilling-permit/ Mugglehead Media en 2026-10-26T12:37:07.349Z Pinnacle Silver and Gold receives permit for 110 El Potrero drill sites CVE: PINN, OTCMKTS: PSGCF, FRA: P9J, Pinnacle Silver and Gold, Gold, Silver, Mexico, Permitting, Exploration https://mugglehead.com/macrogenics-lorigerlimab-linnet-clear-cell-response-safety/ Mugglehead Media en 2026-10-26T12:22:06.463Z MacroGenics reports 25% response in clear cell gynecologic cancer trial NASDAQ: MGNX, NASDAQ: XNCR, NASDAQ: IBB, MacroGenics, Xencor, iShares Biotechnology ETF, Phase 2, Cancer, Bispecific antibodies, Clinical trials https://mugglehead.com/blue-jay-gold-ocean-partners-private-placement/ Mugglehead Media en 2026-10-26T12:12:29.429Z Blue Jay Gold plans C$3M Ocean Partners placement at C$0.90 a unit CVE: JAY, OTCMKTS: JAYGF, FRA: JAY, Blue Jay Gold Corp, Gold, Private placement, Yukon, Steller https://mugglehead.com/graphite-one-dla-carbon-materials-award-terms/ Mugglehead Media en 2026-10-26T12:01:39.657Z Graphite One wins DLA carbon-materials award without disclosing value CVE: GPH, OTCMKTS: GPHOF, Graphite One, Graphite, Defence materials, Alaska, Federal funding https://mugglehead.com/enanta-pharmaceuticals-resolve-zelicapavir-rsv-trial/ Mugglehead Media en 2026-10-26T11:52:07.445Z Enanta Pharmaceuticals starts late-stage RSV trial with 2027 data due NASDAQ: ENTA, LON: GSK, NYSE: GSK, NYSE: PFE, NASDAQ: IBB, Enanta Pharmaceuticals, GSK, Pfizer, iShares Biotechnology ETF, RSV https://mugglehead.com/fury-gold-mines-eau-claire-gold-drilling-true-width/ Mugglehead Media en 2026-10-26T11:30:10.959Z Fury Gold Mines drills 14.95 g/t gold over 4.25m true width at Eau Claire TSE: FURY, NYSEAMERICAN: FURY, Fury Gold Mines, Gold, Drill results, Quebec, Eau Claire https://mugglehead.com/biontech-dualitybio-dynasty-breast02-benefit-lung-toxicity/ Mugglehead Media en 2026-10-26T11:18:35.769Z BioNTech reports modest Phase 3 breast-cancer benefit and lung toxicity NASDAQ: BNTX, HKG: 9606, LON: AZN, NYSE: AZN, BioNTech SE, DualityBio, AstraZeneca, Breast cancer, Phase 3, Antibody-drug conjugates https://mugglehead.com/resolution-minerals-golden-gate-north-gold-zone/ Mugglehead Media en 2026-10-26T00:03:42.171Z Resolution Minerals reports 500m gold zone at Golden Gate North ASX: RML, NASDAQ: RML, Resolution Minerals, Gold, Drill results, Tungsten, Idaho https://mugglehead.com/summit-therapeutics-ivonescimab-biliary-cancer-survival-china/ Mugglehead Media en 2026-10-25T16:17:15.813Z Summit Therapeutics reports 25% lower death risk in biliary-cancer trial NASDAQ: SMMT, HKG: 9926, LON: AZN, NYSE: AZN, Summit Therapeutics, Akeso, AstraZeneca, Biliary tract cancer, Phase 3, Ivonescimab https://mugglehead.com/biontech-bristol-myers-pumitamig-second-line-lung-cancer-phase-2/ Mugglehead Media en 2026-10-25T13:49:46.462Z BioNTech and Bristol Myers report 36.7% response in lung-cancer trial NASDAQ: BNTX, NYSE: BMY, NYSE: LLY, NASDAQ: IBB, BioNTech SE, Bristol Myers Squibb, Eli Lilly and Company, Lung cancer, Phase 2, Immunotherapy https://mugglehead.com/xencor-xmab819-kidney-cancer-dose-response-safety/ Mugglehead Media en 2026-10-25T12:46:07.052Z Xencor reports 45.5% confirmed response at selected kidney-cancer dose NASDAQ: XNCR, NYSE: MRK, NASDAQ: EXEL, Xencor, Merck, Exelixis, Kidney cancer, Phase 1, Bispecific antibodies, Clinical trials https://mugglehead.com/genmab-petosemtamab-colorectal-phase-2-response-follow-up/ Mugglehead Media en 2026-10-25T11:44:53.410Z Genmab reports 75% first-line response in petosemtamab colorectal study NASDAQ: GMAB, NASDAQ: INCY, NASDAQ: IBB, Genmab A/S, Incyte Corporation, iShares Biotechnology ETF, Colorectal cancer, Phase 2, Antibodies, ESMO https://mugglehead.com/lilly-olomorasib-first-line-lung-cancer-response-duration/ Mugglehead Media en 2026-10-25T11:14:43.762Z Lilly reports 14.5-month response duration with olomorasib lung-cancer combination NYSE: LLY, NASDAQ: AMGN, NASDAQ: IBB, Eli Lilly and Company, Amgen Inc, iShares Biotechnology ETF, Lung cancer, KRAS G12C, Clinical trials, Phase 3 https://mugglehead.com/canopy-growth-shareholders-authorize-reverse-stock-split/ Mugglehead Media en 2026-10-25T00:32:27.119Z Canopy Growth Corporation shareholders authorize up to 1-for-15 reverse split TSE: WEED, NASDAQ: CGC, TSE: TLRY, NASDAQ: TLRY, Canopy Growth Corporation, Tilray Brands, Reverse stock split, Shareholder vote, Nasdaq https://mugglehead.com/climb-bio-budoprutug-prismn-kidney-phase-2-data/ Mugglehead Media en 2026-10-24T23:59:00.074Z Climb Bio reports 38% immunologic remission in kidney trial NASDAQ: CLYM, NASDAQ: BIIB, SWX: ROP, OTCMKTS: RHHBY, NASDAQ: IBB, Climb Bio, Biogen, Roche, Phase 2, Kidney disease